Acer Therapeutics Inc. (NASDAQ:ACER) released its earnings results on Monday. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.
Shares of Acer Therapeutics (NASDAQ ACER) opened at $17.89 on Tuesday. Acer Therapeutics has a 12-month low of $5.18 and a 12-month high of $22.63.
Separately, ValuEngine cut shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.